Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mercaptopurine (6-MP) for the Treatment of Manifestations of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)

NCT07716735 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT07716735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07716735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mercaptopurine (6-MP) for the Treatment of Manifestations of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2035
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced kidney carcinoma, advanced renal cell carcinoma, hereditary leiomyomatosis and renal cell carcinoma, metastatic kidney carcinoma, metastatic renal cell carcinoma, skin leiomyoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8, uterine corpus leiomyoma